NCD Drug Label Failure
Resolution 2015-09
 
Whereas, in 2012, Congress passed and the President signed the Food and Drug Administration Safety and Innovation Act (FDASIA), which expressed concerns of the American Council of the Blind relative to the inaccessibility of prescription drug label information to people who are blind or who have low vision; and
 
Whereas, this bill established a working group comprised of representatives of the blind and aging communities, along with the retail pharmacy industry to develop “best practices” for the provision of accessible prescription drug label information under the auspices of the United States Access Board; and
 
Whereas, a comprehensive document was drafted by the working group and released in July 2013; and
 
Whereas, FDASIA further directed the National Council on Disability (NCD) to develop and implement – during a 12-month period immediately following release of the “best practices” document – a campaign to publicize its availability to the blind and aging communities; and
 
Whereas, during this 12-month period, NCD conducted only a single teleconference meeting with the relevant stakeholders and failed to carry out its charge as set forth in this legislation; and
 
Whereas, when queried as to why NCD did nothing to publicize the availability of the “best practices” document, its only response was to indicate that funding for this endeavor was not included in its budget and so no activity could be undertaken;
 
Now, therefore, be it resolved by the American Council of the Blind in convention assembled on the 9th day of July, 2015, at the Sheraton Dallas Hotel, Dallas, Texas, that ACB express its profound disappointment and dissatisfaction with NCD’s total lack of action and blatant disregard for its obligation as outlined in FDASIA to publicize the availability of “best practices” for the provision by retail pharmacies of accessible prescription drug label information.
 
Adopted.
 
Ray Campbell, Secretary